文献速递瓣膜外科

Perceval免缝合主动脉瓣植入的中期结局

Perceval Sutureless Aortic Valve Implantation: Midterm Outcomes.
PubMed 文献 · Ann Thorac Surg · 2020-08-28

该研究纳入2007至2017年连续468例接受Perceval免缝合主动脉瓣置换的患者,平均随访3年、最长11年。结果显示30天全因死亡率为3.2%、早期卒中率1.8%,随访期间无因结构性瓣膜退变而再次手术。

要点

  • Perceval免缝合瓣中期血流动力学良好,平均压差13±6 mm Hg。
  • 30天全因死亡率3.2%,早期卒中率1.8%。
  • 总体起搏器植入率7.9%,无传导或心律异常者仅3.9%。

核心结论

  • Perceval免缝合瓣连续使用超过11年,观察到低死亡率和卒中率,瓣膜血流动力学良好。
  • 随访期间无患者因结构性瓣膜退变而再次手术。

研究设计与样本

  • 单中心回顾性队列,纳入2007至2017年连续468例接受Perceval免缝合主动脉瓣置换的患者。
  • 57%的病例合并其他手术,包括冠状动脉旁路移植39%、二尖瓣手术17%或其他手术13%。

主要发现

  • 平均年龄79岁,平均EuroSCORE II为5.1±5.5,平均STS评分为5.8±5.5。
  • 单纯手术和合并手术的平均主动脉阻断时间分别为39分钟和79分钟。
  • 30天全因死亡率为3.2%,早期卒中率为1.8%。
  • 总体起搏器植入率为7.9%,无既往传导或心律异常者为3.9%。
  • 1年和2年全因死亡率分别为8.8%±1.3%和13.2%±1.6%。

关键数值与推荐

  • 最新超声随访(平均3年,范围1-11年)峰值压差为23±10 mm Hg,平均压差为13±6 mm Hg。
  • 随访期间因感染性心内膜炎取出5枚瓣膜,无因结构性瓣膜退变取出。

临床怎么用

  • Perceval免缝合瓣可用于外科主动脉瓣置换,尤其适合需要快速部署瓣膜的患者。
  • 中期随访显示血流动力学良好且结构性瓣膜退变再手术率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because our center participated in the first-in-human trial with Perceval (LivaNova, Sallugia, Italy) in 2007, this series represents the longest available clinical follow-up (11 years) with sutureless technology in aortic valve replacement. METHODS: We collected all clinical and echocardiographic follow-up in 468 consecutive patients who received Perceval at our institution between 2007 and 2017. In 57% of cases, surgery was combined with coronary artery bypass grafting (39%), mitral valve surgery (17%), or other procedures (13%). RESULTS: Mean age was 79 years, mean EuroSCORE II was 5.1 ± 5.5 (range, 0.8-67) and mean Society of Thoracic Surgeons score was 5.8 ± 5.5. Mean cross-clamp times for isolated and combined procedures were 39 and 79 minutes, respectively. Observed all-cause 30-day mortality was 3.2%, with an early stroke rate of 1.8%. Pacemaker implantation rate was 7.9% overall, but only 3.9% in patients without preexisting conduction or rhythm disorders. All-cause mortality at 1 and 2 years was 8.8% ± 1.3% and 13.2% ± 1.6%, respectively. At the latest echocardiographic follow-up (mean, 3 years; range, 1-11 years), peak and mean gradients were 23 ± 10 mm Hg and 13 ± 6 mm Hg, respectively. During follow-up, we explanted 5 valves for endocarditis, and none for structural valve degeneration. CONCLUSIONS: After more than 11 years of continued clinical use of the Perceval sutureless valve, we observe low mortality and stroke rates, with good hemodynamic behavior of the valve. None of our patients was reoperated for structural valve degeneration. Because of the key benefits of this rapid-deployment valve, it has an added value in surgical aortic valve replacement.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Szecel D, Eurlings R, Rega F, et al. Perceval Sutureless Aortic Valve Implantation: Midterm Outcomes. Ann Thorac Surg. 2020. PMID: 32866479. doi:10.1016/j.athoracsur.2020.06.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。